Modified neonatal B-cell repertoire as a consequence of rituximab administration to a pregnant woman

Rheumatology (United Kingdom)

Volumn 52, Issue 2, 2013, Pages 405-406

  Martínez Martínez, Marco U ^a   Baranda Cándido, Lourdes ^a,b   González Amaro, Roberto ^b   Pérez Ramírez, Oscar ^b   Abud Mendoza, Carlos ^a  

^a UNIVERSIDAD AUTÓNOMA DE SAN LUIS POTOSÍ   (Mexico)

^b Faculty of Medicine   (Mexico)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CD19 ANTIGEN; CD79A ANTIGEN; METHYLPREDNISOLONE; RITUXIMAB;

ADULT; ARTICLE; B LYMPHOCYTE; CASE REPORT; CONTROLLED STUDY; DRUG MEGADOSE; FEMALE; GESTATIONAL AGE; HUMAN; HUMAN CELL; IDIOPATHIC THROMBOCYTOPENIC PURPURA; LYMPHOCYTE SUBPOPULATION; NEWBORN; PREGNANT WOMAN; PREMATURE LABOR; PRIORITY JOURNAL; PROGENY; THROMBOCYTE COUNT; THROMBOCYTOPENIC PURPURA;

ADULT; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTIGENS, CD19; ANTIGENS, CD79; B-LYMPHOCYTE SUBSETS; CELL COUNT; FEMALE; FLOW CYTOMETRY; HUMANS; IMMUNOLOGIC FACTORS; INFANT, NEWBORN; MATERNAL-FETAL EXCHANGE; PREGNANCY; PREGNANCY COMPLICATIONS, HEMATOLOGIC; PURPURA, THROMBOCYTOPENIC, IDIOPATHIC; YOUNG ADULT;

EID: 84873868379     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/kes164     Document Type: Article

References (8)

1. Klink DT, van Elburg RM, Schreurs MW, van Well GT. Rituximab administration in third trimester of pregnancy suppresses neonatal B-cell development. Clin Dev Immunol 2008;2008:271363.
2. Chakravarty EF, Murray ER, Kelman A, Farmer P. Pregnancy outcomes after maternal exposure to rituximab. Blood 2011;117:1499-1506.
3. Saji F, Samejima Y, Kamiura S, Koyama M. Dynamics of immunoglobulins at the feto-maternal interface. Rev Reprod 1999;4:81-89.
4. Chu PG, Arber DA. CD79: a review. Appl Immunohistochem Mol Morphol 2001;9:97-106.
5. Mason DY, Cordell JL, Brown MH et al. CD79a: a novel marker for B-cell neoplasms in routinely processed tissue samples. Blood 1995;86:1453-149.
6. Hardy RR, Hayakawa K. B cell development pathways. Annu Rev Immunol 2001;19:595-621.
7. Teng YK, Levarht EW, Hashemi M et al. Immunohistochemical analysis as a means to predict responsiveness to rituximab treatment. Arthritis Rheum 2007;56:3909-3918.
8. Teng YK, Levarht EW, Toes RE, Huizinga TW, van Laar JM. Residual inflammation after rituximab treatment is associated with sustained synovial plasma cell infiltration and enhanced B cell repopulation. Ann Rheum Dis 2009;68:1011-1016.